Journal of Neuro-Oncology

, Volume 9, Issue 3, pp 255–263 | Cite as

Cisplatin induced neuropathy: Central, peripheral and autonomic nerve involvement

  • Willem Boogerd
  • Wim W. ten Bokkel Huinink
  • Otilia Dalesio
  • Walter J. J. F. Hoppenbrouwers
  • J. Jacob van der Sande
Clinical Study


A prospective study was performed in patients treated with cisplatin to evaluate the occurrence and degree of central, peripheral and autonomic neuropathy and to determine the most accurate method to study this neuropathy. Twelve patients were examined before, during and after treatment. Evaluation included neurologic examination, conventional nerve conduction studies of the median and peroneal nerves and short latency somatosensory evoked potentials (SSER) after median and tibial nerve stimulation. Valsalva maneuvers before and during treatment were performed in 11 patients. Symptoms of peripheral neuropathy paralleled clinical signs. Conventional nerve conduction studies did not seem to be more accurate than clinical examination in determining peripheral neuropathy. SSER appeared to be the most sensitive method for the detection of peripheral nerve impairment. A slowing of central conduction velocity occurred after cumulative doses of 200–400 mg/m2 as measured by SSER. In two patients also some involvement of the autonomic nerves was suggested.

Key words

cisplatin central neurotoxicity peripheral neurotoxicity autonomic neurotoxicity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rozencweig M, Von Hoff DD, Slavik M, Muggia FM: Cisdiamminedichloroplatinum (II). A new anticancer drug. Ann Int Medicine 86: 803–812, 1977Google Scholar
  2. 2.
    Cisplatin (editorial): Lancet 1: 374–375, 1982Google Scholar
  3. 3.
    Kedar A, Cohen ME, Freeman AL: Peripheral neuropathy as a complication of cisdichlorodiammineplatinum (II) treatment: A case report. Cancer Treat Rep 62: 819–821, 1978PubMedGoogle Scholar
  4. 4.
    Thompson SW, Davis LAE, Kornfeld M, Hilgers RD, Standefer JC: Cisplatin neuropathy: clinical, electrophysiologic, morphologic and toxicologic studies. Cancer 54: 1269–1275, 1984PubMedCrossRefGoogle Scholar
  5. 5.
    Hadley D, Herr HW: Peripheral neuropathy associated with cisdichlorodiammineplatinum (II) treatment. Cancer 44: 2026–2028, 1979PubMedCrossRefGoogle Scholar
  6. 6.
    Roelofs RJ, Hrushesky W, Rogin J, Rosenberg L: Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34: 934–938, 1984PubMedGoogle Scholar
  7. 7.
    Ongerboer de Visser BW, Tiessens G: Polyneuropathy induced by cisplatin. Prog exp Tumor Res 29: 190–196, 1985PubMedGoogle Scholar
  8. 8.
    Mollman JE, Hogan WM, Glover DJ, McCluskey LF: Unusual presentation of cis-platinum neuropathy. Neurology 38:488–490, 1988PubMedGoogle Scholar
  9. 9.
    Eeles R, Tait DM, Peckham MJ: Lhermitte's signs as a complication of cisplatin-containing chemotherapy for testicular cancer. Cancer Treat Rep 70: 905–907, 1986PubMedGoogle Scholar
  10. 10.
    Dewar J, Lunt H, Abernethy DA, Dady P, Haas LF: Cisplatin neuropathy with Lhermitte's sign. J Neurol Neurosurg Psychiatry 49: 96–99, 1986PubMedCrossRefGoogle Scholar
  11. 11.
    Walther PJ, Rosbitch E, Bullard DE: The development of Lhermitte's sign during cisplatin chemotherapy. Cancer 60: 2170–2172, 1987PubMedCrossRefGoogle Scholar
  12. 12.
    Gautier-Smith PC: Lhermitte's sign in subacute combined degenetation of the cord. J Neurol Neurosurg Psychiatry 36:861–863, 1972CrossRefGoogle Scholar
  13. 13.
    Rosenfeld CS, Broder LE: Cisplatin-induced autonomic neuropathy. Cancer Treat Rep 68: 659–660, 1984PubMedGoogle Scholar
  14. 14.
    Cohen SC, Mollman JE: Cisplatin-induced gestric paresis. J Neurol Oncol 5: 237–240, 1987CrossRefGoogle Scholar
  15. 15.
    Daugaard GK, Petrera J, Trojaburg W: Electrophysiological study of the peripheral and central neurotoxic effect of cis-platin. Acta Neurol Scand 76: 86–93, 1987PubMedCrossRefGoogle Scholar
  16. 16.
    Ludin HP: Electromyography in Practice. Georg Thieme Verlag, Stuttgart, 1980Google Scholar
  17. 17.
    Cho ES: Toxic effects of adriamycin in the ganglia of the peripheral nervous system: a neuropathological study. J Neuropath Exp Neurol 36: 907–915, 1977PubMedCrossRefGoogle Scholar
  18. 18.
    Kaplan RS, Wiernik PH: Neurotoxicity of antineoplastic drugs. Sem Oncol 9: 103–130, 1982Google Scholar
  19. 19.
    Levin AB: A simple test of cardiac function based upon the heart rate changes induced by the Valsalva maneuver. Am J Cardiol 18: 90–99, 1966PubMedCrossRefGoogle Scholar
  20. 20.
    Hansen SW: Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer. Br Med J 300: 511–512, 1990CrossRefGoogle Scholar
  21. 21.
    Cowan JD, Kies MS, Roth JL, Joyce RP: Nerve conduction studies in patients treated with cis-diamminedochloroplatinum (II): a preliminary report. Cancer Treat Rep 64: 1119–1122, 1980PubMedGoogle Scholar
  22. 22.
    Riggs JF, Ashraf M, Snyder RD, Gurmann L: Prospective nerve conduction studies in cisplatin therapy. Ann Neurol 23: 92–94, 1988PubMedCrossRefGoogle Scholar
  23. 23.
    Clark AW, Parhad IM, Griffin JW, Price DL: Neurotoxicity pf cisplatinum: pathology of the central and peripheral nervous systems. Neurology 30: 429, 1980Google Scholar
  24. 24.
    Walsh TJ, Clark AW, Parhad IM, Green WR: Neurotoxix effects of cisplatin therapy. Arch Neurol 39: 719–720, 1982PubMedCrossRefGoogle Scholar
  25. 25.
    Von Hoff DD, Reichert CM, Cuneo R, Reddick R, Callagher M, Rozencweig M: Demyelination of peripheral nerves associated with cis-diamminedochloroplatinum (II) (DDP) therapy. Proc Am Ass Cancer Res 20: 91, 1979Google Scholar
  26. 26.
    Tomiwa K, Nolan C, Cavanagh JB: The effects of cisplatin on rat spintal ganglia. A study by light and electron microscopy and by morphometry. Acta Neuropathol 69: 295–308, 1986PubMedCrossRefGoogle Scholar
  27. 27.
    Griffin JW, Watson DF: Axonal transport in neurological disease. Ann Neurol 23: 3–13, 1988PubMedCrossRefGoogle Scholar
  28. 28.
    Mollman JE, Glover DJ, Hogan WM, Furman RE: Cisplatin neuropathy. Risk factors, prognosis and protection by protection by WR-2721. Cancer 61: 2192–2195, 1988PubMedCrossRefGoogle Scholar
  29. 29.
    Gerritsen van der Hoop R, Vecht CJ, van der Burg MEL, Elderson A, Boogerd W, Heimans JJ, Vries EP, van Houwelingen JC, Jennekens FGI, Gispen WH, Neyt JP: Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer. N Eng J Med 322: 89–94, 1990CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Willem Boogerd
    • 1
    • 2
  • Wim W. ten Bokkel Huinink
    • 1
  • Otilia Dalesio
    • 1
  • Walter J. J. F. Hoppenbrouwers
    • 2
  • J. Jacob van der Sande
    • 1
    • 2
  1. 1.The Clinical Division of the Netherlands Cancer Institute (Antonie van Leeuwenhoekziekenhuis)The Netherlands
  2. 2.Division of Clinical Neurophysiology of the Municipal Hospital SlotervaartAmsterdamThe Netherlands

Personalised recommendations